Abstracts tagged "Fracture"

Abstract Number: 2122 • ACR Convergence 2025
Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
Maryia Nikitsina¹, Cristina Valero², Miren Uriarte Ecenarro³, Ana M Ortiz³, María Ahijón Lana³, Irene Llorente³, Marina Dueñas-Ochoa⁴, Juan C Saez⁵, EVA GLORIA TOMERO MURIEL⁶, Esther Vicente-Rabaneda⁶, Isidoro Gonzalez-Alvaro⁷, Rosario Garcia Vicuña⁶ and Santos Castañeda⁸, ¹University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ²Hospital de la Princesa, Madrid, Spain, ³Hospital Universitario La Princesa, Madrid, Spain, ⁴Hospital La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Madrid, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Romosozumab (RSZ) is a dual osteoanabolic agent that stimulates bone formation and reduces bone resorption, emerging as a promising option for treating osteoporosis (OP)…
Abstract Number: 0347 • ACR Convergence 2025
Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
Kabyar Cho¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Coeliac disease (CD) is an autoimmune disease, which has been widely reported to be associated with reduced bone mineral density (BMD), leading to an…
Abstract Number: 2119 • ACR Convergence 2025
Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity
Winnie Liu¹, Jeffrey Curtis², Lars Folkestad³, Emily Holladay⁴, Jingyi zhang², Shanette Daigle⁵, Ye Liu², Fenglong Xie⁶ and Eric Orwoll¹, ¹Oregon Health and Science University, Portland, OR, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Southern Denmark, Odense, Denmark, Odense, Denmark, ⁴Foundation for Advancing Science Technology Education and Research, Hoover, AL, ⁵Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁶The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility caused by mutations related to type 1 collagen biosynthesis. Fractures are a…
Abstract Number: 0345 • ACR Convergence 2025
Association Between Deprivation and Fracture Risk in a Regional UK Cohort
Hashem Cheema¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe bay NHS foundation trust, Manchester, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Low socioeconomic status is associated with.an increase in osteoporosis and fracture risk respectively. A multitude of factors have been proposed including income, educational attainment…
Abstract Number: 2116 • ACR Convergence 2025
Romosozumab in Multiple Myeloma Patients at High Risk of Fracture
Giovanni Adami¹, Mariana Diz Lopes², Martina Tinelli², Angela Bonalumi², Ombretta Viapiana² and Maurizio Rossini², ¹University of Verona, Italy, Verona, Italy, ²University of Verona, Verona, Italy
Background/Purpose: Bone damage is a key feature of multiple myeloma (MM). Romosozumab (ROMO), a sclerostin inhibitor, has dual anabolic and antiresorptive properties and may offer…
Abstract Number: 0342 • ACR Convergence 2025
Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study
Edgar Wiebe¹, Benjamin Kuntz², Angela Galindo Santos³, Zhivana Boyadzhieva³, Sandra Hermann¹, Burkhard Muche², Andriko Palmowski², Gerhard Krönke⁴, Ralf Schmidmaier⁵, Kay Raum³ and FRANK BUTTGEREIT⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁵Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, München, Bayern, Germany, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at elevated risk for osteoporotic fragility fractures. Standard assessment via dual-energy X-ray absorptiometry (DXA) does…
Abstract Number: 2108 • ACR Convergence 2025
Multidisciplinary Fragility Fracture Management Across Two Coordinated Hospitals: Evaluating Risk Factors, Treatment Approaches, and Long-Term Patient Outcomes in Those With and Without Prior Fractures
César Antonio Egües Dubuc¹, Nerea Alcorta Lorenzo², Esther Laso Lucas³, Carlos Maria Lizasoain Alustiza⁴, Claudia Murillo Erazo³, Gabriela Jimenez Clemente³, Gaspar de La Herran Nuñez⁴, Vicente Lavilla Garcia³, Imanol Gabarain Morcillo⁴, Leire Unanue Pumar⁴, Irene Corcuera Elosegui⁴, Antonio Martin Garcia⁴, Jorge Jesus Cancio Fanlo⁵, Maria Ariztia Sarratea³, Ander Alberdi Arbelaiz⁴, Iñaki Maria Arruabarrena Echeverria³, Elena Zubillaga Azpiroz⁴ and LUIS LOPEZ DOMINGUEZ⁶, ¹Donostia University Hospital, San Sebastián, Pais Vasco, Spain, ²University Hospital Donostia, san sebastian, Spain, ³Matia Hospital, San Sebastian, Pais Vasco, Spain, ⁴Donostia University Hospital, San Sebastian, Pais Vasco, Spain, ⁵Donostia University Hospital, San Sebastian, ⁶Hospital Universitario Donostia, San Sebastian, Spain
Background/Purpose: Our Fracture Coordination Unit operates across two hospitals: University Hospital of Donostia (UHD) and Matía Hospital (MH). Patients with a geriatric profile are transferred…
Abstract Number: 0341 • ACR Convergence 2025
Romosozumab in patients with Osteoporosis: Safety and Efficacy analysis in Clinical Practice
Daniel Ramos Castro¹, SAMUEL LEAL², ELENA GRAU GARCIA³, Pablo Muñoz-Martínez⁴, Laura Mas Sanchez⁵, Alba Maria Torrat Noves⁶, Belen Villanueva Manes⁷, Iago Alcántara Álvarez⁸, Andres perez Hurtado⁹, Miguel Simeo Vinaixa⁹ and José Andrés Román Ivorra¹⁰, ¹Hospital Universitari i Politecnic La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital La Fe, València, Spain, ⁸Hospital Universitari i Politénic La Fe, València, Spain, ⁹Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Osteoporosis is the most common bone metabolism disorder in developed countries. It increases the risk of fragility fractures, impairing quality of life, increasing disability,…
Abstract Number: 2107 • ACR Convergence 2025
Experience of a Fragility Fracture Coordination Unit Integrated Across Two Hospitals: An Innovative Multidisciplinary Model for Optimizing the Management of Geriatric and Non-Geriatric Patients Beyond Surgery After an Osteoporotic Bone Fragility Fracture
César Antonio Egües Dubuc¹, Esther Laso Lucas², Nerea Alcorta Lorenzo³, Carlos Maria Lizasoain Alustiza⁴, Leire Unanue Pumar⁴, Gabriela Jimenez Clemente², Claudia Murillo Erazo², Vicente Lavilla Garcia², Ander Alberdi Arbelaiz⁴, Elena Zubillaga Azpiroz⁴, Imanol Gabarain Morcillo⁴, Jorge Jesus Cancio Fanlo⁵, Maria Ariztia Sarratea², Iñaki Maria Arruabarrena Echeverria⁴, Gaspar de La Herran Nuñez⁴, Antonio Martin Garcia⁴ and LUIS LOPEZ DOMINGUEZ⁶, ¹Donostia University Hospital, San Sebastián, Pais Vasco, Spain, ²Matia Hospital, San Sebastian, Pais Vasco, Spain, ³University Hospital Donostia, san sebastian, Spain, ⁴Donostia University Hospital, San Sebastian, Pais Vasco, Spain, ⁵Donostia University Hospital, San Sebastian, ⁶Hospital Universitario Donostia, San Sebastian, Spain
Background/Purpose: Fracture Coordination Units typically function within a single hospital using a multidisciplinary approach. Our unit, established in February 2024, pioneers a model coordinating care…
Abstract Number: 0340 • ACR Convergence 2025
Associations with fragility fractures in a population with inflammatory bowel disease (IBD): An observational study.
Chern Lee Choy¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: It is well recognized that inflammatory bowel disease (IBD) is associated with osteoporosis and fragility fractures, likely due to multiple factors, including systemic inflammation,…
Abstract Number: 2106 • ACR Convergence 2025
Prevalence and Characteristics of Morphometric Vertebral Fractures in the Spanish Population: Data from the OsteoSER Study
Carmen Gomez Vaquero¹, Montserrat Roig Kim², Jordi Fiter Areste³, Marta Domínguez-Álvaro⁴, Luis María Jiménez Liñán⁵, Miguel Bernad⁶, Antonio Álvarez-Cienfuegos⁷, Blanca Correa⁸, Antonio Pascual-Vergara⁹, Alejandra Montero Costa¹⁰, Cristina Momblan Trejo¹¹, Manuel Jiménez Rodríguez¹², María Anadón González¹³, Sara Josefina Barcat Zarate¹⁴, Sara Alvar Pariente¹⁵, Cristina Ruiz Pavón¹⁶, Pedro J. Lacalle Chanivet¹⁷, Balbina Marín de Prada¹⁸, Soledad García Frías¹⁹, Francisco Javier Maestro Saavedra²⁰, Marta Poch i Mora²¹, José Luis Gea González²², Carlota Quiroga Fernández²³, Eduardo Acevedo Martel²⁴ and Enrique González-Dávila²⁵, ¹Hospital Universitari de Bellvitge, ⁰⁸⁹⁰⁷ L'Hospitalet, Spain, ²Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ³Hospital Universitari Son Espases, Palma de Mallorca, Spain, ⁴Sociedad Española de Reumatología, Madrid, Spain, ⁵Hospital Don Benito-Villanueva, Don Benito, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Hospital Vega Baja, Orihuela, Spain, ⁸Clínica Sanz y Correa, A Coruña, Spain, ⁹Centro de Salud Ronda-Norte y Ronda-Sur, Ronda, Spain, ¹⁰Centro de Salud Fuencarral, Madrid, Spain, ¹¹Centro de Atención Primaria Viladecans Montbaig, Sant Climent de Llobregat, Spain, ¹²Centro de Salud Don Benito Oeste, Don Benito, Spain, ¹³Consultorio de Pedrezuela, Pedrezuela, Spain, ¹⁴Centro de Salud Orihuela ¹-El Rabaloche, Orihuela, Spain, ¹⁵Centro de Salud Malpica, Malpica, Spain, ¹⁶Centro de Salud Ronda-Norte, Ronda, Spain, ¹⁷Centro de Salud de Santa Amalia, Santa Amalia, Spain, ¹⁸Centro de Atención Primaria Ramona Via i Pros, El Prat de Llobregat, Spain, ¹⁹Centro de Salud de Cortes de la Frontera, Cortes de la Frontera, Spain, ²⁰Centro de Salud Elviña Mesoiro, A Coruña, Spain, ²¹Centro de Atención Primaria CAP ¹⁷ de Setembre, El Prat de Llobregat, Spain, ²²Centro de Salud de Benejúzar, Benezujar, Spain, ²³Centro de Salud Os Mallos, A Coruña, Spain, ²⁴Centro de Salud Ronda-Sur Santa Bárbara, Ronda, Spain, ²⁵Departamento de Matemáticas. Universidad de La Laguna, Tenerife, Spain
Background/Purpose: Most vertebral fractures (VFs) are asymptomatic. Vertebral Fracture Assessment (VFA) using DXA is a low-radiation method to detect morphometric vertebral fractures (MVFs). This study…
Abstract Number: 0246 • ACR Convergence 2025
Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS
Marco Di Paola¹, Fiorella Anna Lombardi¹, Edmund J MacLaughlin², Maurizio Muratore³, Kathleen Methric⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Chiara Stomaci⁷, Roberto Franchini¹, Francesco Conversano¹, Paola Pisani¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁴BoneVue Diagnostics, Catonsville, MD, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Envinronmental Sciences and Technologies, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Intestinal Bowel Diseases (IBD), including Crohn’s (ChD), and Ulcerative Colitis (UCD), along with Celiac (ClD), diseases are chronic inflammatory conditions that primarily affect the…
Abstract Number: 2070 • ACR Convergence 2025
Characterization of Hospitalization, Patient Demographics and Impact of Idiopathic Inflammatory Myopathies on Hospitalization Outcomes in Adult Fracture Patients: A National Inpatient Sample Analysis.
Pranathi Bandarupalli¹, Vineeth Potluri², Amr Alemairy², Harsharn Grewal² and Shudipan Chakraborthy², ¹Mercy St Vincent Medical Center, Toledo, OH, ²Mercy Health St. Vincent Medical Center, Toledo, OH
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), including polymyositis and dermatomyositis, are rare systemic autoimmune disorders characterized by chronic muscle inflammation and progressive muscle weakness. Patients with…
Abstract Number: 2115 • ACR Convergence 2025
METHOFRACT, a methotrexate osteopathy multicentric binational cohort study.
François ROBIN¹, Roba Ghossan², Nadia Mehsen-Cetre³, Louise Triquet¹, Guillaume LARID⁴, Guillaume Coiffier⁵, Marine Mina⁶, Marie-Eva Pickering⁷, Claire Barthe⁸, Julien Paccou⁹, Julien Herman¹⁰, Emmanuel Massy¹¹, Isabelle Roitg¹², Martine Branquet¹³, Julien Lasnier Siron³, Manon Guillouard¹⁴, Camille Desmonet Trousset¹⁵, Aurore Aubrun¹⁶, Bertrand Godfrin¹⁷, Jean-Philippe Hauzeur¹⁸, Emmanuel Chatelus¹⁹, Eugénie Koumakis², Jean-Louis Legrand²⁰, Thierry Schaeverbeke³, Alexia Leloix¹, Maeva Masson²¹, Julia Nicolau¹⁵, Charles Ghiringhelli²², Marijke Decrock¹², Durel Cécile-Audrey²³, Béatrice Bouvard²⁴, Bernard Cortet⁹, Charlotte Casadepax-Soulet²⁵, Olivier Malaise⁶, Rose Marie Javier²⁶, Karine Briot² and Pascal Guggenbuhl¹, ¹Rennes University Hospital, Rennes, France, ²APHP, Paris, France, ³Bordeaux University Hospital, Bordeaux, France, ⁴Poitiers University Hospital - Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France, ⁵Dinan Hospital, Dinan, France, ⁶Liege University Hospital, Liège, Belgium, ⁷Clermon-Ferrand University Hospital, Clermont-Ferrand, France, ⁸Clinique Tivoli Ducos, Bordeaux, France, ⁹Lille University Hospital, Lille, France, ¹⁰La Roche Sur Yon Hospital, La Roche-sur-Yon, France, ¹¹Lyon University Hospital, Lyon, France, ¹²Perpignan Hospital, Perpignan, France, ¹³Ploemeur Rheumatology Liberal Structure, Ploemeur, France, ¹⁴Aurillac Hospital, Aurillac, France, ¹⁵Dieppe Hospital, Dieppe, France, ¹⁶Nice Rheumatology Liberal Stucture, Nice, France, ¹⁷St Gaudens Rheumatology Liberal Structure, St Gaudens, France, ¹⁸Liege University Hospital, Liege, Belgium, ¹⁹Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ²⁰Arras Hospital, Arras, France, ²¹Toulouse University Hospital, Toulouse, France, ²²Pauillac Rheumatology Liberal Structure, Pauillac, France, ²³Saint Joseph Saint Luc Hospital, Lyon, France, ²⁴Angers University Hospital, Angers, France, ²⁵West Reunion Hospital, Saint Paul, France, ²⁶Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Methotrexate-induced osteopathy is a rare condition. The clinical presentation is often typical, associating lower limb involvement with metaphyseal bone fractures/cracks, mainly of the tibia…
Abstract Number: 1997 • ACR Convergence 2025
Bone health in patients with gout using real-world U.S. data
Emily Holladay¹, Alexis Woods², Fenglong Xie³, Jingyi Zhang¹, Angelo Gaffo⁴, Jeffrey Curtis⁵ and Brian Lamoreaux⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Amgen, Detroit, MI, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁶Amgen, Inc., Deerfield, IL
Background/Purpose: Patients with gout may be at high risk for developing osteoporosis and fractures, but osteoporosis may be under-recognized and inadequately managed for gout patients.…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].